stockrow
Friday 6 November 2026
Export BWAY’s income statement to Excel — free account
Brainsway Ltd. Sponsored ADR
BWAY Healthcare Medical Devices
Brainsway Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $52.2 million, up 27.3% from fiscal 2024.
- Revenue
- +35.4%
- EPS
- +40.0%
- Free cash flow
- −51.7%
Quarter to June 2026, against a year earlier
11.14
0.53
+5.00%
Follow BWAY
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
31.02 | 28.89 | 23.78 | 47.09 |
+8 more quarters Free account |
P/S ratio |
4.95 | 4.51 | 3.46 | 6.01 | |
P/FCF ratio |
51.89 | 21.90 | 11.93 | 16.08 | |
P/Operating CF |
47.62 | 216.58 | (139.98) | 212.84 | |
P/B ratio |
3.79 | 3.35 | 2.47 | 4.21 | |
Price to Tangible BV |
3.79 | 3.35 | 2.47 | 4.21 | |
EV/Sales |
3.95 | 3.49 | 2.19 | 4.60 | |
EV/EBITDA |
25.97 | 26.69 | 19.48 | 47.77 | |
EV/Operating CF |
31.66 | 14.39 | 6.53 | 10.15 | |
EV/FCF |
41.42 | 16.96 | 7.54 | 12.33 | |
Quick Ratio |
3.11 | 2.87 | 3.27 | 2.96 | |
Current Ratio |
3.59 | 3.34 | 3.73 | 3.19 | |
Net Debt/EBITDA |
(22.39) | (24.30) | (30.59) | (43.32) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.52 | 0.52 | 0.50 | 0.53 | |
Operating CF/Net income |
2.33 | 0.51 | (0.45) | 0.89 | |
Capex/Depreciation |
(2.00) | (1.65) | 1.90 | (1.98) | |
Interest Coverage |
2.72 | 6.29 | 7.15 | 2.19 | |
Research and Development Expense of Revenue |
18.82% | 18.55% | 17.40% | 17.73% | |
Selling, General and Administrative Expense of Revenue |
41.83% | 43.71% | 45.86% | 48.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.89% | 2.20% | 1.93% | 2.69% | |
Graham Net Nets |
0.13 | 0.15 | 0.24 | 0.14 | |
Graham Number |
6.78 | 6.41 | 5.89 | 5.08 | |
Earnings Yield |
3.22% | 3.46% | 4.21% | 2.12% | |
Free Cash Flow Yield |
1.93% | 4.57% | 8.38% | 6.22% | |
Revenue per Share |
0.88 | 0.81 | 0.77 | 0.69 | |
Operating CF per Share |
0.33 | 0.06 | (0.07) | 0.07 | |
Capex per Share |
(0.05) | (0.04) | 0.04 | (0.04) | |
Free Cash Flow per Share |
0.28 | 0.02 | (0.03) | 0.03 | |
Cash per Share |
3.28 | 3.15 | 3.65 | 3.67 | |
Shareholders Equity per Share |
4.09 | 3.97 | 3.85 | 3.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.09 | 3.97 | 3.85 | 3.58 | |
Free Cash Flow |
5.42 | 0.40 | (0.62) | 0.59 | |
Working Capital |
58.75 | 55.07 | 61.33 | 56.94 | |
Capital Expenditures |
(0.88) | (0.77) | 0.67 | (0.80) | |
Net Current Asset Value |
38.64 | 37.43 | 43.80 | 39.94 | |
EV/EBIT |
31.68 | 34.15 | 26.42 | 79.66 | |
Capex to Sales |
0.05 | 0.05 | (0.05) | 0.06 | |
Price to Operating Income |
39.69 | 44.09 | 41.80 | 103.94 | |
| Other line items | |||||
Average Receivables |
5.45 | 7.24 | 4.35 | 4.33 | |
Average Payables |
1.86 | 2.52 | 2.65 | 2.03 | |
Average Inventory |
5.75 | 5.88 | 5.47 | 4.05 | |
Average Assets |
116.77 | 108.60 | 103.75 | 92.58 | |
Average Common Equity |
73.66 | 69.77 | 67.74 | 57.05 |
Columns are period end dates · fundamentals updated 26 Oct 2026